PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors
Recruiting
N/A
Interventional Study
Solid Tumor
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 50 (estimated)
- Sponsor
- Hua Zhu · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To utilize the \[68Ga\]Ga-THP-PDL1-3 molecular probe to non-invasively detect PD-L1 expression in primary and metastatic lesions of patients with solid tumors. Furthermore, to assess the heterogeneity of PD-L1 expression within the same lesion and across different lesions, and to observe changes in PD-L1 expression during the course of treatment. This approach aims to facilitate patient screening,…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age 18-70 years, ECOG score 0 or 1;
2. Patients with solid tumors;
3. Presence of measurable lesions on imaging examinations;
4. Expected survival ≥12 weeks.
Exclusion Criteria:
1. Severe hepatic or renal dysfunction;
2. Women who are planning pregnancy, pregnant, or breast…
Contacts